NDA 220605 · Takeda Pharms Am
Mimrylo
Rusfertide Acetate · Subcutaneous
NovelPriority reviewOrphanCDER novel approval, Aug 28, 2026: To treat erythrocytosis in adults with polycythemia vera
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 28, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 7, 2026.
MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is a hepcidin mimetic indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV). ( 1 )
Mechanism: Rusfertide is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. Inhibition of ferroportin by rusfertide reduces availability of iron for production of red blood cells resulting in lower hematocrit levels.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 28, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
5 products under this application
- MIMRYLO · RUSFERTIDE ACETATE EQ 54MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
- MIMRYLO · RUSFERTIDE ACETATE EQ 28MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
- MIMRYLO · RUSFERTIDE ACETATE EQ 9.5MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
- MIMRYLO · RUSFERTIDE ACETATE EQ 41MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
- MIMRYLO · RUSFERTIDE ACETATE EQ 19MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rusfertide" as an intervention, any sponsor and status, largest first.
- A Study of Rusfertide in Adults With Polycythemia Vera (PV)Pivotal-lookingActive, not recruiting
Protagonist Therapeutics, Inc.Industry
NCT05210790 · 293 participants · Start Apr 11, 2022 · Primary completion Feb 21, 2025
Drug: Rusfertide; Placebo · For: Polycythemia Vera
Sites: Mobile, Alabama; Glendale, Arizona; Duarte, California · 184 sites in all
- Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraPivotal-lookingActive, not recruiting
Protagonist Therapeutics, Inc.Industry
NCT06033586 · 46 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Open-label rusfertide · For: Polycythemia Vera
Sites: Covington, Louisiana
- A Study of Rusfertide in Adults With Polycythemia Vera in ChinaNot yet recruiting
TakedaTakeda (TAK)
NCT07765602 · 24 participants (planned) · Start Mar 1, 2027 · Primary completion Jul 1, 2028
Drug: Rusfertide · For: Polycythemia Vera
Protagonist Therapeutics, Inc.Industry
NCT04767802 · 20 participants · Start Feb 2, 2021 · Primary completion Mar 15, 2023
Drug: PTG-300 · For: Polycythemia Vera
Sites: Johor Bahru, Malaysia; Kota Bharu, Malaysia; Ipoh, Malaysia · 8 sites in all
Protagonist Therapeutics, Inc.Industry
NCT04202965 · 16 participants · Start Mar 19, 2020 · Primary completion Oct 6, 2021
Drug: PTG-300 · For: Hereditary Hemochromatosis
Sites: Fayetteville, Georgia; Bethesda, Maryland; Charlotte, North Carolina · 11 sites in all
TakedaTakeda (TAK)
NCT07648030 · 9 participants (planned) · Start Jul 14, 2026 · Primary completion Oct 28, 2027
Drug: Rusfertide · For: Polycythemia Vera
Sites: Nagoya, Japan; Maebashi, Japan; Tsu, Japan · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M, Kuykendall AT, Pemmaraju N, et al. · N Engl J Med 2024 · Multicenter Study, Randomized Controlled Trial
- Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
Modi NB, Shames R, Lickliter JD, et al. · Eur J Haematol 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
- Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Modi NB, Khanna S, Rudraraju S, et al. · Drugs R D 2024 · Randomized Controlled Trial
- Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.
Modi NB, Dinh P, Ajari I · Clin Pharmacol Drug Dev 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
- Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV, Modi NB, Peltekian K, et al. · Lancet Gastroenterol Hepatol 2023 · Clinical Trial, Phase II, Multicenter Study
- Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants.
Modi NB, Dinh P, Xue H, et al. · Clin Ther 2025 · Randomized Controlled Trial
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.